SENtinel Lymph Node Mapping With GAllium-68-tilmanocept PET/CT in High/High-intermediate Risk Endometrial Cancer: a Pilot Study
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
This pilot study evaluates the feasibility of 68Ga-tilmanocept PET/CT for SLN mapping in patients with endometrial cancer.
Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Healthy Volunteers: f
View:
• Clinical FIGO 2012 stage I-II high/high-intermediate risk endometrial cancer;
• Scheduled for robot-assisted full pelvic and para-aortic staging;
• Age ≥18 years and able to provide informed consent.
Locations
Other Locations
Netherlands
Cornelis G Gerestein
RECRUITING
Utrecht
Contact Information
Primary
Cornelis G Gerestein, MD, PhD
C.G.Gerestein-2@umcutrecht.nl
+31616770541
Backup
Ilse G.T. Baeten, MD
i.g.t.baeten@umcutrecht.nl
Time Frame
Start Date: 2023-02-15
Estimated Completion Date: 2024-09-01
Participants
Target number of participants: 10
Treatments
Experimental: 68Ga-tilmanocept PET/CT
All participants receive 68Ga-tilmanocept PET/CT imaging in adjunct to standard-of-care (SLN mapping with intraoperative ICG).
Related Therapeutic Areas
Sponsors
Leads: UMC Utrecht